{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:56:37Z","timestamp":1788504997238,"version":"build-2803163510"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1001\/jamaneurol.2020.2734","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T14:56:46Z","timestamp":1597071406000},"page":"1504","source":"Crossref","is-referenced-by-count":98,"title":["Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment"],"prefix":"10.1001","volume":"77","author":[{"given":"Joshua D.","family":"Grill","sequence":"first","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine"},{"name":"Institute for Clinical and Translational Science, University of California, Irvine, Irvine"},{"name":"Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine"},{"name":"Department of Neurobiology and Behavior, University of California, Irvine, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Ernstrom","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Sultzer","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine"},{"name":"VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Burns","sequence":"additional","affiliation":[{"name":"University of Kansas Alzheimer's Disease Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Donohue","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Molecular Imaging and Nuclear Medicine, Department of Radiology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Karlawish","sequence":"additional","affiliation":[{"name":"Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia"},{"name":"Department of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"A4 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi200058r1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi200058r2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"23","key":"noi200058r3","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1001\/jama.2011.810","article-title":"Changing concepts of Alzheimer disease.","volume":"305","author":"McKhann","year":"2011","journal-title":"JAMA"},{"issue":"18","key":"noi200058r4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1001\/jama.287.18.2335","article-title":"Alzheimer disease.","volume":"287","author":"Cummings","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"noi200058r5","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.","volume":"66","author":"Morris","year":"2009","journal-title":"Arch Neurol"},{"issue":"22","key":"noi200058r6","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons.","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"noi200058r7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease.","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"noi200058r8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi200058r9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria.","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi200058r10","doi-asserted-by":"publisher","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association.","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"15","key":"noi200058r11","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1212\/WNL.0b013e31826e26db","article-title":"Predicting positivity for a new era of Alzheimer disease prevention trials.","volume":"79","author":"Burns","year":"2012","journal-title":"Neurology"},{"issue":"14","key":"noi200058r12","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1212\/WNL.0000000000001451","article-title":"Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"228","key":"noi200058r13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"noi200058r14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals.","volume":"77","author":"Sperling","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"noi200058r15","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1097\/01.wad.0000213879.55547.57","article-title":"ADCS prevention instrument project: the Mail-In Cognitive Function Screening Instrument (MCFSI).","volume":"20","author":"Walsh","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"noi200058r17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/bjc.1992.31.issue-3","article-title":"The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).","volume":"31","author":"Marteau","year":"1992","journal-title":"Br J Clin Psychol"},{"issue":"12","key":"noi200058r19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"2","key":"noi200058r20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/sltb.2019.49.issue-2","article-title":"Determinants and predictive value of clinician assessment of short-term suicide risk.","volume":"49","author":"Barzilay","year":"2019","journal-title":"Suicide Life Threat Behav"},{"issue":"3","key":"noi200058r21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00002093-200007000-00003","article-title":"Illness representations among first-degree relatives of people with Alzheimer disease.","volume":"14","author":"Roberts","year":"2000","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"noi200058r22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00006842-197905000-00004","article-title":"Impact of event scale: a measure of subjective stress.","volume":"41","author":"Horowitz","year":"1979","journal-title":"Psychosom Med"},{"issue":"1","key":"noi200058r23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","article-title":"Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.","volume":"7","author":"Harkins","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"noi200058r25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13195-018-0398-3","article-title":"Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.","volume":"10","author":"de Wilde","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"noi200058r26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jalz.2017.01.022","article-title":"Safety of disclosing amyloid status in cognitively normal older adults.","volume":"13","author":"Burns","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi200058r27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jalz.2015.09.005","article-title":"Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability.","volume":"12","author":"Lim","year":"2016","journal-title":"Alzheimers Dement"},{"key":"noi200058r28","doi-asserted-by":"crossref","DOI":"10.1177\/1533317520904551","article-title":"Disclosure of amyloid status for risk of alzheimer disease to cognitively normal research participants with subjective cognitive decline: a longitudinal study.","volume":"35","author":"Wake","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"5","key":"noi200058r29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1041610217002204","article-title":"The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline.","volume":"30","author":"Wake","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"noi200058r30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0809578","article-title":"Disclosure of APOE genotype for risk of Alzheimer\u2019s disease.","volume":"361","author":"Green","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"noi200058r31","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2019.0797","article-title":"Attitudes toward physician-assisted death from individuals who learn they have an alzheimer disease biomarker.","volume":"76","author":"Largent","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi200058r32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13195-018-0452-1","article-title":"Reactions to learning a \u201cnot elevated\u201d amyloid PET result in a preclinical Alzheimer\u2019s disease trial.","volume":"10","author":"Grill","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"noi200058r33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229137","article-title":"Cognitively unimpaired adults\u2019 reactions to disclosure of amyloid PET scan results.","volume":"15","author":"Largent","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"noi200058r34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamaneurol.2017.2954","article-title":"Comprehension of an elevated amyloid positron emission tomography biomarker result by cognitively normal older adults.","volume":"75","author":"Mozersky","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi200058r35","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jalz.2008.04.007","article-title":"Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer\u2019s disease.","volume":"4","author":"Cassidy","year":"2008","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi200058r36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamaneurol.2018.4910","article-title":"Early awareness of Alzheimer disease: a neurologist\u2019s personal perspective.","volume":"76","author":"Gibbs","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi200058r37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13195-016-0223-9","article-title":"Desire for predictive testing for Alzheimer\u2019s disease and impact on advance care planning: a cross-sectional study.","volume":"8","author":"Sheffrin","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"15","key":"noi200058r38","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1212\/WNL.0b013e31826e2696","article-title":"Indicators of amyloid burden in a population-based study of cognitively normal elderly.","volume":"79","author":"Mielke","year":"2012","journal-title":"Neurology"},{"key":"noi200058r39","article-title":"Association of anxiety with subcortical amyloidosis in cognitively normal older adults.","author":"Hanseeuw","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"3","key":"noi200058r40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/jamapsychiatry.2014.2476","article-title":"Amyloid-\u00df, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.","volume":"72","author":"Pietrzak","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"noi200058r41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jalz.2016.06.2360","article-title":"Systematic review of dementia prevalence and incidence in United States race\/ethnic populations.","volume":"13","author":"Mehta","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"6","key":"noi200058r42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamaneurol.2019.0165","article-title":"Preclinical Alzheimer disease and the dawn of the pre-caregiver.","volume":"76","author":"Largent","year":"2019","journal-title":"JAMA Neurol"},{"key":"noi200058r16","first-page":"165","volume-title":"Clinical Gerontology: A Guide to Assessment and Intervention.","author":"Sheikh","year":"1986"},{"key":"noi200058r18","volume-title":"Manual for the State-Trait Anxiety Inventory","author":"Spielberger","year":"1983"},{"key":"noi200058r24","unstructured":"Agency for Healthcare Research and Quality. Use the teach-back method: tool #5. Published 2015. https:\/\/www.ahrq.gov\/health-literacy\/quality-resources\/tools\/literacy-toolkit\/healthlittoolkit2-tool5.html"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2769022\/jamaneurology_grill_2020_oi_200058_1607448141.57528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T13:40:22Z","timestamp":1607953222000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2769022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.2734","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}